Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Fernández-Ciriza, L. (Leire) | - |
dc.creator | Gonzalez-Hernandez, A. (Alvaro) | - |
dc.creator | Pozo, J.L. (José Luis) del | - |
dc.creator | Fernandez-Montero, A. (Alejandro) | - |
dc.creator | Carmona-Torre, F. (Francisco de A.) | - |
dc.creator | Carlos-Chillerón, S. (Silvia) | - |
dc.creator | Sarasa-Monreal, M.M. (Mari Mar) | - |
dc.creator | Reina, G. (Gabriel) | - |
dc.date.accessioned | 2022-11-11T14:30:38Z | - |
dc.date.available | 2022-11-11T14:30:38Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | Fernández-Ciriza, L. (Leire); González-Hernández, Á. (Álvaro); del Pozo-León, J. (José Luis); et al. "Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain". Scientifics Reports. 12 (1), 2022, 15606 | es |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://hdl.handle.net/10171/64640 | - |
dc.description.abstract | Scarce data have been reported about cellular immunity and longevity for different COVID-19 vaccination schedules. We carried out a prospective study enrolling 709 healthcare workers receiving two doses of mRNA-1273, BNT162b2, ChAdOx1, ChAdOx1/BNT162b2 or ChAdOx1 single dose to compare humoral and cellular immunogenicity across 9 months. Higher SARS-CoV-2 spike antibody levels were observed among individuals with hybrid immunity with one dose of any vaccine in comparison to uninfected individuals receiving two doses (mRNA-1273: 20,145 vs 4295 U/mL; BNT162b2: 15,659 vs 1959 U/mL; ChAdOx1: 5344 vs 2230 U/mL), except for ChAdOx1/BNT162b2 heterologous schedule (12,380 U/mL). Naturally infected individuals did not increase substantially the titers after the second dose and showed higher levels throughout the 9 months follow-up. The mean elimination half-life of antibodies among COVID-19 naive participants was 98, 111, 60 and 36 days, for mRNA-1273, BNT162b2, ChAdOx1/ChAdOx1 and ChAdOx1/BNT162b2, respectively. Cellular immunity was preserved in 96%, 98%, 88% and 92% of uninfected individuals who received mRNA-1273, BNT162b2, ChAdOx1/ChAdOx1 and ChAdOx1/BNT162b2 after 6/9 months. Individuals with specific T cells showed robust long lasting protection, especially when m-RNA based vaccines are inoculated. These data may influence the validity of the vaccination passport and the need for booster vaccinations. | - |
dc.description.sponsorship | This study was funded by a Grant from Roche International (Reference: SAVIN). | - |
dc.language.iso | en | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Área de Biomedicina | - |
dc.title | Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.description.note | This article is licensed under a Creative Commons Attribution 4.0 International License | - |
dc.identifier.doi | 10.1038/s41598-022-19537-2 | - |
dadun.citation.number | 1 | - |
dadun.citation.publicationName | Scientifics Reports | - |
dadun.citation.startingPage | 15606 | - |
dadun.citation.volume | 12 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.